Kristin C Comella
Chief Science Officer USSC
Dr. Comella is a world-renowned expert on regenerative medicine with a focus on adipose derived stem cells. She was named number 24 on Terrapin’s list of the Top 50 Global Stem Cell Influencers and number 1 on the Academy of Regenerative Practices list of Top 10 Stem Cell Innovators. Most recently, Dr. Comella made the list of Top 50 Functional and Integrative Medical Doctors/Scientists in the country by DrAxe.com, one of the most visited natural health websites in the world.
Dr. Comella has pioneered stem cell therapies from various sources including cord blood, bone marrow, muscle, and adipose. She led the team that gained the first ever FDA approval for a clinical trial using a combined cell and gene therapy product in the heart. In addition to advanced cell culturing experience, Dr. Comella has managed the development, manufacturing, and quality systems of a variety of cellular products. She has developed a wide range of regenerative techniques and products that have now been successfully implemented into the clinic setting. Her professional experience includes positions in several companies including US Stem Cell, VetBiologics, Tulane University and Osiris Therapeutics. Dr. Comella progressed from research engineer at Osiris Therapeutics developing stem cell therapies for osteoarthritis to building and managing the stem cell laboratory at Tulane University’s Center for Gene Therapy. She was the co-founder and Chief Executive Officer of Stemlogix, a regenerative medicine company focusing on veterinary medicine.
She is currently serving as the Chief Scientific Officer and board member of US Stem Cell, a publicly traded company focusing on the discovery, development, and commercialization of autologous cell therapies for the treatment of degenerative diseases. She has been responsible for the development and implementation of cell therapies in the clinic for a variety of different indications for more than 7000 patients. Hundreds of practitioners world-wide have provided stem cell treatments to their patients using her protocols. Dr. Comella has a PhD in Stem Cell Biology and holds both an MS and BS in Chemical Engineering.
William P. Murphy, Jr., M.D.
Chairman of the Board USSC
Dr. William P. Murphy, Jr., currently serves as the Chairman of the Board of U.S. Stem Cell, having joined as a member of the Board of Directors in June 2003. Dr. Murphy is a medical doctor and inventor of medical devices which have redefined the standards of medical care. His contributions include the first physiologic cardiac pacemaker; the widely used hollow fiber artificial kidney; the first disposable medical procedural trays; the first motor-driven angiographic injectors; and the first disposable catheters. Dr. Murphy holds 17 U.S. patents issued between 1952 and 1980.
Dr. Murphy was the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer during his 28 years at Cordis until his retirement in October, 1985. Cordis Johnson & Johnson is a global leader in cardiovascular instrumentation. Dr. Murphy is the recipient of a number of prestigious honors, including the Lemelson-MIT Lifetime Achievement Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology and he was inducted into the National Inventors Hall of Fame in 2008 and the American Institute of Medical and Biological Engineering as a Founding Fellow.
Dr. Murphy graduated from Harvard University in 1946. He received his M.D. in 1947 from the University of Illinois and also studied physiologic instrumentation at the Massachusetts Institute of Technology from 1947 to 1948. He is the son of the American physician William Parry Murphy who shared the Nobel Prize in Physiology for Medicine in 1934.
J. S. Landow, M.D.
Managing Director ASC
Dr. Landow, has been involved in Healthcare for almost 30 years and he is currently the Managing Director of Advanced Stem Cell Rx, which is building the largest network of autologous stem cell treatment centers in the US.
Dr. Landow first became engaged as a healthcare consultant over 20 years ago, and has worked with several of the largest and nationally prominent Health Systems along with numerous Wall Street firms and advising on medical-industry acquisitions, IPO’s and recapitalizations involving biotechnology, bio-medical devices and healthcare service companies.
In 1994 he founded New York Medical, Inc. (”NYM”), one of the pioneering practice management companies. NYM quickly established itself as one of the region’s leading specialty practice management entities, offering extensive vertical integration and turnkey solutions. and encompassed the following specialties: neurology, spine and orthopedic surgery, pain management, physiatry, physical & occupational therapy, acupuncture, and internal medicine.
He has served on the Medical advisory board for the Juvenile Diabetes Foundation and the development board of The Feinstein Institute for Medical Research, which is the research branch of the Northwell Health. Dr. Landow earned his B.A. in Economics at Vassar College in New York, subsequently completing an M.S. in Nutrition and Biochemistry at Columbia University in New York. He earned his M.D. at the University of Miami, School of Medicine.